The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 215-226

  Juillerat Jeanneret, Lucienne ^a,b   Gerber Lemaire, Sandrine ^a,b  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b EPFL   (Switzerland)

Author keywords

Diabetes; Dipeptidyl aminodipeptidase IV; Fibroblast activation protease ; Fibrogenic disorders; Specific inhibition

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; 8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; ABT 279; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPEPTIDYL PEPTIDASE IX; DIPEPTIDYL PEPTIDASE VIII; GLUCAGON LIKE PEPTIDE 1; GSK 823093; PEPTIDE HYDROLASE INHIBITOR; PROLINE; PROLYL DIPEPTIDASE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SAXAGLIPTIN; SEPRASE; SITAGLIPTIN; TALABOSTAT; UNCLASSIFIED DRUG; VILDAGLIPTIN; AMINOPEPTIDASE; ENZYME INHIBITOR; FAP PROTEIN, HUMAN; PROLINE IMINOPEPTIDASE; SERINE PROTEINASE; TUMOR ANTIGEN; TUMOR MARKER;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GENETIC CONSERVATION; HUMAN; IMMUNOMODULATION; LIVER FIBROSIS; LUNG FIBROSIS; MACROPHAGE; MYOFIBROBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; T LYMPHOCYTE; ANIMAL; DRUG ANTAGONISM; FIBROSIS; METABOLISM;

AMINOPEPTIDASES; ANIMALS; ANTIGENS, NEOPLASM; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENZYME INHIBITORS; FIBROSIS; HUMANS; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 65449165652     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709787316100     Document Type: Review

References (107)

1. Abbott, C.A.; Yu, D.M.; Woollatt, E.; Sutherland, G.R.; McCaughan, G.W.; Gorrell, M.D. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur. J. Biochem., 2000, 267, 6140-50.
2. Ajami, K.; Abbott, C.A.; McCaughan, G.W.; Gorrell, M.D. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim. Biophys. Acta, 2004, 1679, 18-28.
3. Chen, W.T.; Kelly, T.; Ghersi, G. DPPIV, seprase, and related serine peptidases in multiple cellular functions. Curr. Top. Dev. Biol., 2003, 54, 207-32.
4. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. USA, 2003, 100, 5063-68.
5. Guan, E.; Wang, J.; Norcross, M.A. Amino-terminal processing of MIP-1β/CCL4 by CD26/dipeptidyl-peptidase IV. J. Cell Biochem., 2004, 92, 53-64.
6. Hiramatsu, H.; Yamamoto, A.; Kyono, K.; Higashiyama, Y.; Fukushima, C.; Shima, H.; Sugiyama, S.; Inaka, K.; Shimizu, R. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. Biol. Chem., 2004, 385, 561-4.
7. Leiting, B.; Pryor, K.D.; Wu, J.K.; Marsilio, F.; Patel, R.A.; Craik, C.S.; Ellman, J.A.; Cummings, R.T.; Thornberry, N.A. Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII. Biochem. J., 2003, 371, 525-32.
8. Lambeir, A.M.; Durinx, C.; Scharpe, S.; De Meester, I. Dipeptidyl peptidase IV from bench to bedside: an update on structural properties, functions and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sc., 2003, 40, 209-94.
9. Mentlein, R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept., 1999, 85, 9-24.
10. Park, J.E.; Lenter, M.C.; Zimmermann, R.N.; Garin-Chesa, P.; Old, L.J.; Rettig, W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem., 1999, 274, 36505-12.
11. Polgar, L. The prolyl oligopeptidase family. Cell. Mol. Life Sci., 2002, 59, 349-62.
12. Rasmussen, H.B.; Branner, S.; Wiberg, F.C.; Wagtmann, N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat. Struct. Biol., 2003, 10, 19-25.
13. Rosenblum, J.S.; Kosarich, J.W. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr. Opin. Chem. Biol., 2003, 7, 496-504.
14. Mentlein, R. Exp. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Opin. Invest. Drugs, 2005, 14, 57-64.
15. Juillerat-Jeanneret, L. Prolyl-specific peptidases and their inhibitors in biological processes. Curr. Chem. Biol., 2008, 2, 97-109.
16. Evans, D.M. Dipeptidyl peptidase IV inhibitors. Drugs, 2002, 5, 577-585.
17. Weber, A.E. Dipeptidyl peptidase iv inhibitors for the treatment of diabetes. J. Med. Chem., 2004, 47, 4135-41.
18. Deacon, C.F. MK-431 (Merck) Curr. Opin. Invest. Drugs, 2005, 6, 419-26.
19. Holst, J.J.; Deacon, C.F. Perspectives in Diabetes: inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes, 1998, 47, 1663-70.
20. Holst, J.J.; Deacon, C.F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Phamacol., 2004, 4, 589-96.
21. Chen, W.T.; Kelly, T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev, 2003, 22, 259-69.
22. Chen, W.T. DPPIV and seprase in cancer invasion and angiogenesis. Adv. Exp. Med. Biol., 2003, 524, 197-203.
23. Ariga, N.; Sato, E.; Ohuchi, N.; Nagura, H.; Ohtani, H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int. J. Cancer, 2001, 95, 67-72.
24. Huber, M.A.; Kraut, N.; Park, J.E.; Schubert, R.D.; Rettig, W.J.; Peter, R.U.; Garin-Chesa, P. Fibroblast activation protein: Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J. Invest. Dermatol., 2003, 120, 182-8.
25. Huang, Y.; Wang, S.; Kelly, T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res., 2004, 64, 2712-6.
26. Morrison, M.E.; Vijayasaradhi, S.; Engelstein, D.; Albino, A.P.; Houghton, A.N. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J. Exp. Med., 1993, 177, 1135-43.
27. Scott, A.M.; Wiseman, G.; Welt, S.; Adjei, A.; Lee, F.T.; Hopkins, W.; Divgi, C.R.; Hanson, L.H.; Mitchell, P.; Gansen, D.N.; Larson, S.M.; Ingle, J.N.; Hoffmann, E.W.; Tanswell, P.; Ritter, G.; Cohen, L.S.; Bette, P.; Arvay, L.; Amelsberg, A.; Vlock, D.; Rettig, W.J.; Old, L. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. J. Clin. Cancer Res., 2003, 9, 1639-47.
28. Pineiro-Sanchez, M.L.; Goldstein, L.A.; Dodt, J.; Howard, L.; Yeh, Y.; Chen, W.T. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J. Biol. Chem., 1997, 272, 7595-601.
29. Aimes, R.T.; Zijlstra, A.; Hooper, J.D.; Ogbourne, S.M.; Sit, M.L.; Fuchs, S.; Gotley, D.C.; Quigley, J.P.; Antalis, T.M. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thrombosis Haemostasis, 2003, 89, 561-72.
30. Iwasa, S.; Jin, X.; Okada, K.; Mitsumata, M.; Ooi, A. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett., 2003, 199, 91-8.
31. Iwasa, S.; Okada, K.; Chen, W.T.; Jin, X.; Yamane, T.; Ooi, A. 'Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett., 2005, 227, 229-36.
32. Chen, D.; Kennedy, A.; Wang, J.Y.; Zeng, W.; Zhao, Q.; Pearl, M.; Zhang, M.; Suo, Z.; Nesland, J.M.; Qiao, Y.; Ng, A.K.; Hirashima, N.; Yamane, T.; Mori, Y.; Mitsumata, M.; Ghersi, G.; Chen, W.T. Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res., 2006, 66, 9977-85.
33. Okada, K.; Chen, W.T.; Iwasa, S.; Jin, X.; Yamane, T.; Ooi, A.; Mitsumata, M. Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology, 2003, 65, 363-70.
34. Goodman, J.D.; Rozypal, T.L.; Kelly, T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin. Exp. Metastasis, 2003, 20, 459-70.
35. Gorrell, M.D. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin. Sci., 2005, 108, 277-92.
36. Levy, M.T.; McCaughan, G.W.; Abbott, C.A.; Park, J.E.; Cunningham, A.M.; Müller, E.; Rettig, W.J.; Gorrell, M.D. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology, 1999, 29, 1768-78.
37. Wang, X.M.; Yu, D.M.; McCaughan, G.W.; Gorrell, M.D. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology, 2005, 42, 935-45.
38. a) Ghersi, G.; Dong, H.; Goldstein, L.A.; Yeh, Y.; Hakkinen, L.; Larjava, H.S.; Chen, W.T. Seprase-DPPIV association and prolyl peptidase and gelatinase activities of the protease complex. Adv. Exp. Med. Biol., 2003, 524, 87-94
39. b) Ghersi, G.; Zhao, Q.; Salamone, M.; Yeh, Y.; Zucker, S.; Chen, W.T. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res., 2006, 66, 4652-61.
40. Thornberry, N.A.; Weber, A.E. Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem., 2007, 7, 557-68.
41. Kleppinger, E.L.; Helms, K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann. Pharmacother., 2007, 41, 824-32.
42. Gallwitz, B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today, 2007, 43, 13-25.
43. Thompson, M.A.; Ohnuma, K.; Abe, M.; Morimoto, C.; Dang, N.H. CD26/ dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med. Chem., 2007, 7, 253-73.
44. Ristic, S.; Byiers, S.; Foley, J.; Holmes, D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes. Metab., 2005, 7, 692-98.
45. Iwata, S.; Yamaguchi, N.; Munakata, Y.; Ikushima, H.; Lee, J.F.; Hosono, O.; Schlossmann, S.F.; Morimoto, C. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol., 1999, 11, 417-26.
46. Iwata, S.; Morimoto, C. CD26/dipeptidyl peptidase IV in context: the different roles of a multifunctional ectoenzyme in malignant transformation. J. Exp. Med., 1999, 190, 301-5.
47. Pethiyagoda, C.L.; Welch, D.R.; Fleming, T.P. Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clin. Exp. Metastasis, 2001, 18, 391-400.
48. Pro, B.; Dang, N.H. CD26/dipeptidyl peptidase IV and its role in cancer. Histol. Histopathol., 2004, 19, 1345-51.
49. Wesley, U.V.; Albino, A.P.; Tiwari, S.; Houghton, A.N. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J. Exp. Med., 1999, 190, 311-22.
50. Wesley, U.V.; Tiwari, S.; Houghton, A.N. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int. J. Cancer, 2004, 109, 855-66.
51. Aratake, Y.; Umeki, K.; Kiyoyama, K.; Hinoura, Y.; Sato, S.; Ohno, A.; Kuribayashi, T.; Hirai, K.; Nabeshima, K.; Kotani, T. Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn. Cytopathol., 2002, 26, 366-72.
52. Asada, Y.; Aratake, Y.; Kotani, T.; Marutsuka, K.; Araki, Y.; Ohtaki, S.; Sumiyoshi, A. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology, 1993, 23, 265-70.
53. Kajiyama, H.; Kikkawa, F.; Maeda, O.; Suzuki, T.; Ino, K.; Mizutani, S. Increased expression of dipeptidyl peptidase iv in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology, 2002, 63, 158-65.
54. Kajiyama, H.; Kikkawa, F.; Ino, K.; Shibata, K.; Mizutani, S. Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade. Adv. Exp. Med. Biol., 2003, 524, 245-8.
55. Kajiyama, H.; Kikkawa, F.; Khin, E.; Shibata, K.; Ino, K.; Mizutani, S. Dipeptidyl peptidase IV overexpression induces upregulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res., 2003, 63, 2278-83.
56. Kikkawa, F.; Kajiyama, H.; Shibata, K.; Ino, K.; Nomura, S.; Mitzutani, S. Dipeptidyl peptidase IV in tumor progression. Biochim. Biophys. Acta, 2005, 1751, 45-51.
57. Cheng, H.C.; Abdel-Ghany, M.; Zhang, S.; Pauli, B.U. Is the Fischer 344/ CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer? Clin. Exp. Metastasis, 1999, 17, 609-15.
58. Cheng, H.C.; Abdel-Ghany, M.; Elble, R.C.; Pauli, B.U. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J. Biol. Chem., 1998, 273, 24207-15.
59. Adams, S.; Miller, G.T.; Jesson, M.I.; Watanabe, T.; Jones, B.; Wallner, B,P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res., 2004, 64, 5471-80.
60. Christopherson, K.W.; Hangoc, C.; Broxmeyer, H.E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1α -mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol., 2002, 169, 7000-8.
61. Guan, E.; Wang, J.; Norcross, M.A. Amino-terminal processing of MIP-1β/CCL4 by CD26/dipeptidyl-peptidase IV. J. Cell. Biochem., 2004, 92, 53-64.
62. Lim, J.K.; Burns, J.M.; Lu, W.; DeVico, A.L. Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. J. Leuk. Biol., 2005, 78, 442-52.
63. Proost, P.; Struyf, S.; Schols, D.; Opdenaker, G.; Sozzani, S.; Allavena, P.; Mantovani A.; Augustyns, K.; Bal, G.; Haemers, A.; Lambeir, A.M.; Scharpé, S.; Van Damme, J.; De Meester, I.. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem., 1999, 274, 3988-93.
64. Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol., 2008, 214, 199-210.
65. Lupher, M.L.; Gallatin, W.M. Regulation of fibrosis by the immune system. Adv. Immunol., 2006, 89, 245-88.
66. Roberts, A.B.; Tian, F.; Da Costabyfield, S.; Stuelten, C.; Ooshima, A.; Saika, S.; Flanders, K.C. Smad3 is key to TGF-β -mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cyt. Growth Factor Rev., 2006, 17, 19-27.
67. Radisky, D.C.; Kenny, P.A.; Bissell, M.J. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J. Cell. Biochem., 2007, 101, 830-9.
68. Egidy, G.; Juillerat-Jeanneret, L.; Jeannin, J.F.; Korth, P.; Bosman, F.T.; Pinet, F. Modulation of human colon tumor-stromal interactions by the endothelin system. Am. J. Pathol., 2000, 157, 1863-74.
69. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol., 2003, 200, 500-3.
70. Kernochan, L.E.; Tran, B.N.; Tangkijvanich, P.; Melton, A.C.; Tam, S.P.; Yee, H.F. Endothelin-1 stimulates human colonic myofibroblast contraction and migration. Gut, 2002, 50, 65-70.
71. Poncet, S.; Meyer, S.; Richard, C.; Aubert, J.D.; Juillerat-Jeanneret, L. The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse. Am. J. Obst. Gynecol., 2005, 192, 426-32.
72. Serini, G.; Gabbiani, G. Mechanisms of Myofibroblast Activity and Phenotypic Modulation. Exp. Cell Res., 1999, 250, 273-83.
73. Vaughan, M.B.; Howard, E.W.; Tomasek, J.J. Transforming growth factor-β 1 promotes the morphological and functional differentiation of the myofibroblast. Exp. Cell Res., 2000, 257, 180-9.
74. Seki, E.; De Minicis, S.; Österreicher, C.H.; Kluwe, J.; Osawa, Y.; Brenner, D.A.; Schwabe, R.F. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med., 2007, 13, 1324-32.
75. Busek, P.; Malik, R.; Sedo, A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int. J. Biochem. Cell Biol., 2004, 36, 408-21.
76. De Meester, I.; Lambeir, A.M.; Proost, P.; Scharpé, S. Dipeptidyl peptidase IV substrates: an update on in vitro peptide hydrolysis by human DPPIV. Adv. Exp. Med. Biol., 2003, 524, 3-17.
77. De Meester, I.; Vanhoof, G.; Hendriks, D.; Demuth, H.U.; Yaron, A.; Scharpé, S. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin. Chim. Acta, 1992, 210, 23-34.
78. Oefner, C.; D'Arcy, A.; Mac Sweeney, A.; Pierau, S.; Gardiner, R.; Dale, G.E. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-({2-(5-iodopyridin-2-yl)amino-ethyl}amino)- acetyl-2-cyano-(S)-pyrrolidine. Acta Crystallogr., 2003, D59, 1206-12.
79. Thoma, R.; Löffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV. Structure, 2003, 11, 947-59.
80. Aertgeerts, K.; Ye, S.; Tennant, M.G.; Kraus, M.L.; Rogers, J.; Sang, B.-C.; Skene, R.J.; Webb, D.R.; Prasad, G.S. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci., 2004, 13, 412-21.
81. Gwaltney, S.L., II; Stafford, J.A. nhibitors of dipeptidyl peptidase 4. Ann. Rep. Med. Chem., 2005, 40, 149-65.
82. a) McIntosh, C.H.S. Dipeptidyl peptidase IV inhibitors and diabetes therapy. Front. Biosci., 2008, 13, 1753-73
83. b) McIntosh, C.H.S.; Demuth, H.-U.; Kim, S.-J.; Pospisilik, J.A.; Pederson, R.A. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int. J. Biochem. Cell Biol., 2006, 38, 860-72.
84. Von Geldern, T.W.; Trevillyan, J.M. The next big thing in diabetes: clinical progress on DPP-IV inhibitors. Drug Dev. Res., 2006, 67, 627-42.
85. Hoffmann, T.; Glund, K.; McIntosh, C.H.S.; Pederson, R.A.; Hanefeld, M.; Rozenkranz, B.; Demuth, H.U. DPIV-inhibition as treatment of type II diabetes. In Cell-Surface Aminopeptidases: Basic and Clinical aspects, Mizutani, S. Ed.; Kluwer: New-York, 2001, pp 381-7.
86. Wargent, E.; Stocker, C.; Augstein, P.; Heinke, P.; Meyer, A.; Hoffmann, T.; Subramanian, A.; Sennitt, M.V.; Demuth, H.-U.; Arch, J.R.S.; Cawthorne, M. A. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. Diabetes Obes. Metab., 2005, 7, 170-81.
87. Ashton, W.T.; Dong, H.; Sisco, R.M.; Doss, G.A.; Leiting, B; Patel, R.A.; Wu, J.K.; Marsilio, F.; Thornberry, N.A., Weber, A.E. Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 859-63.
88. Mastracchio, A.; Parmee, E.R.; Leiting, B.; Marsilio, F.; Patel, R.; Thornberry, A.E.; Edmonson, S.D. Heterocycle fused cyclohexylglycine derivatives as novel dipeptidyl peptidase-IV inhibitors. Heterocycles, 2004, 62, 203-6.
89. Magnin, D.R.; Robl, J.A.; Sulsky, R.B.; Augeri, D.J.; Huang, Y.; Simpkins, L.M.; Taunk, P.C.; Betebenner, D.A.; Robertson, J.G.; Abboa-Offei, B.E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D.F.; Malley, M.F.; Gougoutas, J.Z.; Khanna, A.; Huang, Q.; Han, S.-P.; Parker, R.A.; Hamann, L.G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of α -aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhibitors. J. Med. Chem., 2004, 47, 2587-98.
90. Ahrén, B. DPP-4 inhibitors. Best Pract. Res. Clin. Endocr. Metab., 2007, 21, 517-33.
91. Idris, I.; Donnelly, R. ipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug Diabetes, Obes. Metab., 2007, 9, 153-65.
92. Deacon, C.F.; Carr, R.D.; Holst, J.J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front. Biosci., 2008, 13, 1780-94.
93. Pei, Z.; Li, X.; Lomgenecker, K.; von Geldern, T.W.; Wiedeman, P.E.; Lubben, T.H.; Zinker, B.A.; Stewart, K.; Ballaron, S.J.; Stashko, M.A.; Mika, A.K.; Beno, D.W.A.; Long, M.; Wells, H.; Kempf-Grote, A.J.; Madar, D.J.; McDermott, T.S.; Bhagavatula, L.; Fickes, M.G.; Pireh, D.; Solomon, L.R.; Lake, M.R.; Edalji, R.; Fry, E.H.; Sham, H.L.; Trevillyan, J.M. Discovery, structureactivity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors. J. Med. Chem., 2006, 49, 3520-35.
94. Thomas, L.; Eckhardt, M.; Langkopf, E.; Tadayyon, M.; Himmelsbach, F.; Mark, M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2- ynyl-3-methyl-1-(4-methyl-quinazolin-2 -ylmethyl)-3,7-dihydropurine- 2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J. Pharm. Exp. Ther., 2008, 325, 175-82.
95. Wang, Y. Alogliptin benzoate: dipeptidyl-peptidase IV (DPP IV) inhibitor treatment of type 2 diabetes. Drugs Future, 2008, 33, 7-12.
96. Gao, Y.-D., Feng, D.; Sheridan, R.P.; Scapin, G.; Patel, S.B.; Wu, J.K.; Zhang, X.; Sinha-Roy, R.; Thornberry, N.A.; Weber, A.E.; Biftu, T. Modeling assisted rational design of novel, potent, and selective pyrrolopyrimidine DPP-4 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 3877-9.
97. Aertgeerts, K.; Levin, I.; Shi, L., Snell, G.P.; Jennings, A.; Prasad, G.S.; Zhang, Y.; Kraus, M.L.; Salakian, S.; Sridhar, V.; Wijnands, R.; Tennant, M.G. Tructural and kinetic analysis of the substrate specificity of human fibroblast activation protein α. J. Biol. Chem., 2005, 280, 19441-4.
98. Edosada, C.Y.; Quan, C.; Wiesmann, C.; Tran, T.; Sutherlin, D.; Reynolds, M.; Elliott, J.M.; Raab, H.; Fairbrother, W.; Wolf, B.B. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J. Biol. Chem., 2006, 281, 7437-44.
99. Edosada, C.Y.; Quan, C.; Tran, T.; Pham, V.; Wiesmann, C.; Fairbrother, W.; Wolf, B.B. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2-Pro1-cleaving specificity. FEBS Lett., 2006, 580, 1581-6.
100. Meadows, S.A.; Edosada, C.Y.; Mayeda, M., Tran, T.; Quan, C.; Raab, H.; Wiesmann, C.; Wolf, B.B. Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization. Biochemistry, 2007, 46, 4598-4605.
101. a) Adams, S.; Miller, G.T.; Jesson, M.I.; Watanabe, T.; Jones, B.; Wallner, B.P. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res., 2004, 64, 5471-80
102. b) McIntyre, J.A.; Castañer, J. Talabostat Drugs Future, 2004, 29, 882-6.
103. c) Nemunaitis, J., Vukelja, S.J.; Richards, D.; Cunningham, C.; Senzer, N.; Nugent, J.; Duncan, H.; Jones, B.; Haltom, E.; Uprichard, M.J. Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy. Cancer Invest., 2006, 24, 553-61.
104. Tran, T.; Quan, C.; Edosada, C.Y.; Mayeda, M.; Wiesmann, C.; Sutherlin, D.; Wolf, B.B. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP. Bioorg. Med. Chem. Lett., 2007, 17, 1438-42.
105. Bachovchin, W.W.; Lai, H.-S. Inhibitors of fibroblast activation protein alpha. PCT WO07/005991, 2007.
106. Gilmore, B.F.; Lynas, J.F.; Scott, C.J.; McGoohan, C.; Martin, L.; Walker, B. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPα). Biochem. Biophys. Res. Commun., 2006, 346, 436-46.
107. Wang, X.M.; Yao, T.-W.; Nadvi, N.A.; Osborne, B.; McCaughan, G.W.; Gorrell, M.D. Fibroblast activation protein and chronic liver disease. Front. Biosci., 2008, 13, 3168-80.